Top Banner
Heider SH. Qassam MSc. PH. & TH.
43

Heider SH. Qassam MSc. PH. & TH.. Heart transplantation It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Jan 17, 2016

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Heider SH. QassamMSc. PH. & TH.

Page 2: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.
Page 3: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Heart transplantationIt is a widely accepted therapy for

most patients under 65 years of age with advanced heart failure who remain symptomatic with the expectation of high intermediate term mortality, despite optimal heart failure medications.

Page 4: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Heterotopic Heart TransplantationThe phrase `heterotopic' describes

placing the heart in an ectopic position without removing the native heart. The heterotopic technique has been used in experimental transplantation.

It can be categorized into `working' and `nonworking' models.

It has several advantages , including technical simplicity, better accessibility for biopsies, and survival of the recipient even in case of graft rejection.

Page 5: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Transplantation–Induced (I/R) Injury Organ transplantation is a unique situation where

grafts are successively subjected to global cold ischemia, warm ischemia, and blood reperfusion.

These events are believed to impair graft function.

The pathophysiology of (I/R) injury shows several characteristics of inflammatory responses including activation of complement, endothelial cells, infiltration of neutrophils, the release of oxygen–derived free radicals, and cytokines.

Page 6: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Pathogenesis of Myocardial (I/R) Injury

Ion accumulation Intracellular calcium overload. Increased intracellular sodium.Decrease in pH with rapid normalization

upon reperfusion.

Page 7: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Dissipation of mitochondrial membrane potential

MPTPFree radical formation/ROSGeneration from xanthine oxidase.Release of reactive mitochondrial

intermediates.Neutrophil infiltration.

Page 8: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

NO metabolismLoss of NO-vasodilation.Accumulation of reactive peroxynitrite.

Apoptosis Endothelial dysfunctionCytokine and chemokine signaling.Expression of cellular adhesion markers. Impaired vasodilation.

Page 9: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Immune activationInnate immunity (e.g.,

complement activation, expression of Toll-like receptors)

Neutrophil accumulationCell-mediated damage

(macrophage and T cell)

Page 10: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Proinflammatory Mediators in Myocardial

(I/R) InjuryTumour necrosis factor alpha It is a pleiotropic cytokine that has many

proinflammatory actions with negative inotropic effects.

It is produced by a host in response to inflammation, tissue injury and has recently been recognized as a myocardial depressant substance.

TNF-α is released from macrophages, monocytes and mast cells within minutes in response to myocardial I/R injury.

Page 11: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Interleukine-1 Beta IL-1β is a proinflammatory cytokine produced

by activated macrophages and monocytes. It functions in the generation of systemic and local responses to infection, injury, and is the primary cause of inflammation.

It has functions similar to TNF-α such as induction of chemokine production and expression of adhesion molecules by endothelial cells.

IL-1β plays a crucial role in initiating inflammatory responses and in recruitment and activation neutrophils to inflammation sites.

Page 12: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Intercellular Adhesion Molecule (ICAM-1)

It is a member of the immunoglobulin superfamily and is critical for the firm arrest and transmigration of leukocytes out of blood vessels and into tissues.

ICAM-1 plays an important role in the early stages of cardiac damage following ischemia–reperfusion injury. In this process, ICAM-1-mediated leukocyte adhesion and subsequent infiltration into the infarct area could be responsible for myocyte damage via released free radicals.

Page 13: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Cardiac Troponin I

Troponin I is a contractile protein " Part of the thin filament regulatory complex that confers calcium sensitivity to the ATP activity of the striated muscle actin-myosin complex".

cTnI was found exclusively in cardiac muscle and thus making it a specific marker for myocardial injury.

Page 14: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

MK-886 It is a highly potent inhibitor of leukotriene

formation. This compound inhibits leukotriene

biosynthesis indirectly by a mechanism through the binding of a membrane bound (FLAP), thereby inhibiting the translocation and activation of 5-lipoxygenase which is catalyses the conversion of arachidonic acid to (LTA4).

Page 15: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

It was found to be a potent and specific inhibitor of both LTB4 and LTC4 synthesis in human phagocytes and moderately potent PPARα antagonist.

It was also found to prevents postischemic leukotriene accumulation after I/R .

Page 16: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

DITPA It is a TH analog with positive inotropic

activity but minimal effect on heart rate or metabolic rate compared with thyroid hormone itself.

DITPA can promote angiogenesis by interacting with membrane-bound integrin αVβ3 and activating the MAPK cascade.

DITPA attenuates the acute inflammatory response and reduces myocardial infarct size following myocardial ischemia .

Page 17: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

DITPA enhances endothelial NO-mediated vasorelaxation.

DITPA prevent abnormal sarcoplasmic reticulum calcium transport and abnormal contractile function associated with MI.

Page 18: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Aim of the Study this study was undertaken to assess

the possible protective effect of MK-886 and DITPA against global myocardial I/R injury after heart transplantation via interfering with inflammatory pathways.

Page 19: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.
Page 20: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

The rats were randomized into six groups as followSham group: rats underwent the same anesthetic and surgical procedures but with no HHT .Control group: rats underwent 30 min of global myocardial ischemia followed by 60 min of reperfusion via HHT.

Page 21: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Control vehicle (1) group: Donors rats received vehicle of MK-886 30 min before HHT, and the same dose was repeated for recipients upon reperfusion.

Control vehicle (2) group: Donors and recipients rats pretreated with DITPA vehicle for 7days before HHT.

MK-886 treated group: Donors rats received MK-886 (0.6 mg/kg) i.p. 30 min before HHT , and the same dose was repeated for recipients upon reperfusion.

DITPA treated group: Donors and recipients rats pretreated with DITPA(3.75 mg/kg) s.c. for 7days before HHT.

Page 22: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Methods Overview

Isolate donor heart

Bilateral thoractomy was made, and interior chest wall was opend.

All the vessels, except the aorta and pulmonary artery, were ligated

The heart removed & stored in cold lactated ringer solution.

Prepare recipient animals

The right CA was exposed and then occluded with clamp.

Distal portion of CA was ligated

CA was then incised and passed through cuff.

REJV was prepared the in same way.

Heart

transplantation

The donor heart was placed in the right neck of the recipient.

The arterial cuff was inserted into donor aorta and fixed with a ligature.

IV cuff was inserted into the donor PA and fixed with ligature.

Page 23: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Operation Heart transplantation

Prepare recipient rats

Isolated donor heart

Page 24: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Preparation of Samples Blood Sampling for

measurement of plasma cTnIAt the end of experiment, about 2 ml of

blood was collected from the heart and placed in a tube containing Na2EDTA and used for determination plasma cTnI.

Tissue Sampling for Histopathology

The apical part of the heart was fixed in 10% formalin to be used for histopathological evaluation

Page 25: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Tissue preparation for TNF-α, IL-1β and ICAM-1 measurement

10% homogenates of heart tissue were prepared in PBS that contained 1% Triton X-100 and a protease inhibitor cocktail.

The homogenate was centrifuged at 2,500 g for 20 min at 4°C. The supernatant was

collected for determination of TNF-α, IL-1β and ICAM-1.

Page 26: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Histopathological Evaluation of Rat Heart

The scoring system for histological findings was divided into 4 scores:

Score 0, no damage. Score 1, interstitial edema and focal necrosis. Score 2, diffuse myocardial cell swelling and

necrosis. Score 3, necrosis with the presence of contraction

bands, neutrophil infiltration and the capillaries were compressed.

Score 4, widespread necrosis with the presence of contraction bands, neutrophil infiltration, capillaries compressing and hemorrhage.

Page 27: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Statistical Analysis ANOVA test was used for the multiple

comparison among all groups followed by post-hoc tests using LSD method.

Mann-Whitney and Krusakl-Wallis tests were used to assess the statistical significance of

histopathological parameters. Pearson correlation coefficient was used to assess the associations between two quantitative

variable. Spearman correlation coefficient was used to

assess the associations between two quantitative variable when one of them was non-normally

distributed.

Page 28: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.
Page 29: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (6): The mean of cardiac TNF-α level (pg/ml) in the six experimental groups at the end of the experiment.

*

Ѱ,*†,*

* vs. sham group, ѱ vs. control vehicle (1) group, †vs. control vehicle (2) group.

The data expressed as mean ±SEM (p<0.05)

This result is consistent with Gurevitch et al. (1996) were the first to demonstrate a significant release of TNF-α in the rat coronary effluent at 1 min after reperfusion.

Page 30: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (7): The mean of cardiac IL-1β level (pg/ml) in the six experimental groups at the end of the experiment.

*

Ѱ,*†,*

* vs. sham group, ѱ vs. control vehicle (1) group, †vs. control vehicle (2) group.

The data expressed as mean ±SEM (p<0.05)

This result is consistent with Herskowitz et al . (1995) demonstrated induced myocardial gene expression of IL-1β after permanent LAD occlusion and temporary LAD occlusion followed by reperfusion.

Page 31: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

*

Ѱ,* †,*

This result is in agreement with Kukielka et al. (1993) ) were reported that ICAM-1 gene expression increased in reperfused myocardium after 1 hr coronary occlusion and 1 hr reperfusion

This result is in agreement with Kukielka et al. (1993) ) were reported that ICAM-1 gene expression increased in reperfused myocardium after 1 hr coronary occlusion and 1 hr reperfusion

Figure (8): The mean of cardiac ICAM-1 level (pg/ml) in the six experimental groups at the end of the experiment

* vs. sham group, ѱ vs. control vehicle (1) group, †vs. control vehicle (2) group.

The data expressed as mean ±SEM (p<0.05)

Page 32: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (9): The mean of plasma (cTnI) level (ng/ml) in the six experimental groups at the end of the experiment

* vs. sham group, ѱ vs. control vehicle (1) group, †vs. control vehicle (2) group.

The data expressed as mean ±SEM (p<0.05)

This result is consistent with Bertinchant et al. (1999) ) showed that cTnI released in 1 min during 60 min of reperfusion after 20 min, 30 min, 40 min or 60 min of global ischemia by using Langendorff-perfused rat hearts model.

This result is consistent with Bertinchant et al. (1999) ) showed that cTnI released in 1 min during 60 min of reperfusion after 20 min, 30 min, 40 min or 60 min of global ischemia by using Langendorff-perfused rat hearts model.

*

Ѱ,*†,*

Page 33: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (11): Error bar chart shows the difference in mean ±SEM values of total severity scores in the six experimental groups.

*

Ѱ,*†,*

This result is cosistent with zingarelli et al. (2002) showed that a marked disruption of the myocardial structure in I/R injury was characterized by appearance of extensive necrosis and contraction bands.

This result is cosistent with zingarelli et al. (2002) showed that a marked disruption of the myocardial structure in I/R injury was characterized by appearance of extensive necrosis and contraction bands.

* vs. sham group, ѱ vs. control vehicle (1) group, †vs. control vehicle (2) group.

The data expressed as mean ±SEM (p<0.05)

Page 34: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (12 ): Photomicrograph of cardiac section of normal rats shows the normal architecture.

The section stained with Haematoxylin and Eosin (X 40).

Page 35: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (13): Photomicrograph of cardiac section showed interstitial edema and focal necrosis. The section stained

with Haematoxylin and Eosin (X 40).

Page 36: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (14): Photomicrograph of cardiac section

showed neutrophil infiltration (arrows). The section

stained with Haematoxylin and Eosin (X 40).

Page 37: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (15): Photomicrograph of cardiac section showed capillary compressing. The section stained with Haematoxylin and Eosin (X 40).

Page 38: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (16 ): Photomicrograph of cardiac section showed contraction bands. The section stained with Haematoxylin and Eosin (X 40).

Page 39: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (17): Photomicrograph of cardiac section

showed hemorrhage. The section stained with

Haematoxylin and Eosin (X 40).

Page 40: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Figure (18 ): Photomicrograph of cardiac section in MK-886 treated group. The section stained with Haematoxylin and Eosin (X 40).

Figure (19): Photomicrograph of cardiac section in DITPA treated group. The section stained with Haematoxylin and Eosin (X 40).

Page 41: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Conclusions The findings of this study suggest the

followings: Both MK-886 and DITPA ameliorate myocardial injury

associated with HT by reducing inflammatory mediators and adhesion molecule. This may give an evidence for their protective effect.

Both MK-886 and DITPA reduce cTnI associated with MI/R injury induced by HT which is a specific marker for cardiac injury.

This study supports the hypothesis that inflammatory pathways are involved in global MI/R injury induced by HT.

Page 42: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.

Recommendations we recommend the following:These findings have put MK-886 and DITPA as a future therapeutic agents in situations including global MI/R injury following heart transplantation through their interfering with inflammatory pathways.

Measuring of cardiac myeloperoxidase activity to estimate tissue PMNs accumulation in inflamed hearts.Measuring of infarct size to evaluate the cytoprotection of drugs used in this study and this is done by (TTC) staining.

Measuring of LTB4 and LTC4 in the heart to further

support their role in the pathogenesis of MI/R injury.

Page 43: Heider SH. Qassam MSc. PH. & TH.. Heart transplantation  It is a widely accepted therapy for most patients under 65 years of age with advanced heart.